The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis
Abstract
Aim To evaluate the magnitude of venous and arterial thrombosis risk associated with antiphospholipid antibodies (APLs) in adults without systemic lupus erythematosus (SLE).Methods Case-control and cohort studies were selected from the MEDLINE and Cochrane Library databases. Two investigators independently extracted data on study design, patient characteristics, venous and arterial events and exposure to APLs, including lupus anticoagulant (LA), anticardiolipin (aCL), anti-β2 Glycoprotein I (β2GpI), anti-prothrombin (aPT), anti-phosphatidyl serine (aPS), and anti-phosphatidyl ethanolamine (aPE).Results 30 studies were included (16,441 patients). The odds ratio (OR) for venous thrombosis was 6.14 (95% confidence interval [CI] 2.74-13.8) in LA-positive patients (5 studies, 1650 patients) and 1.46 (CI 1.06-2.03) in aCL-positive patients (12 studies, 5375 patients). None of the associations with more recently identified APLs was significant, but fewer studies were available. For arterial thrombosis, the OR for LA and aCL was 3.58 (CI 1.29-9.92) and 2.65 (CI 1.75-4.00) respectively. The associations between β2GpI, aPT and aPS and the risk of arterial thrombosis were also significant, the OR being 3.12 (CI 1.51-6.44), 2.95 (CI 1.31-6.66) and 6.00 (CI 3.07-11.7), respectively. Owing to the heterogeneity of cut-off values for each APL assay, we were unable to perform any sensitivity analysis to determine the optimal value. The presence of low-quality studies may have led to overestimation of the magnitude of the associations.Conclusions LA and aCL were significantly associated with an increased risk of thrombosis, especially arterial, in patients without SLE. Systematic thromboprophylaxis in high-risk patients with APL should be evaluated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In most studies, it has been shown that in SLE, LA is the main predictor of thrombosis [9, 27–29].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [27]
In the citing paper
“Notably, most prior efforts to risk-stratify patients for future thrombotic events have used the patients’ aPL status from the first measurement or early in the observation period and have not analyzed changes over time.3,7,8”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [7]
In the citing paper
“Although a positive LAC is considered to be a strong risk factor for thrombosis in APS, 10,11”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [11]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Systematic Reviews in Health Care. Meta-analysis in Context.
Kleijnen, J., & Antes, G. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.3.697 · Cited by 1,374
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 875
Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-997 · Cited by 526
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Schulman, S., Svenungsson, E., & Granqvist, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00060-6 · Cited by 497
Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 468 · cited 4×
“[61], asymptomatic APL carriers characterized by a high-risk APL profile (triple positivity) experienced a higher incidence of thrombotic events: 5.”
BackgroundInfluentialEpidemiology of the Antiphospholipid Antibody Syndrome
Petri, M. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0409 · Cited by 468
Research works printed but not linked: 2
- Fijnheer, 1994, Antiphospholipid antibodies in patients with thrombo-embolic disease, Lupus, 3, 361
- Simioni, 1994, Lupus anticoagulant and antiphospholipid antibodies in outpatients with clinically suspected DVT, Lupus, 3, 361
Cited by
Sorted by citations
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
Zuo, Y., Estes, S. K., Ali, R. A., Gandhi, A. A., Yalavarthi, S., Shi, H., Sule, G. J., Gockman, K., Madison, J. A., Zuo, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3876 · Cited by 658
de Abreu, M. M., Danowski, A., Wahl, D. G., Amigo, M., Tektonidou, M. G., Pacheco, M. D. S., Fleming, N. R. P., Domingues, V., Sciascia, S., Lyra, J. O., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.002 · Cited by 227
Self-citationThe clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 212
Sammaritano, L. R. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101463 · Cited by 211
Viall, C. A., & Chamley, L. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.008 · Cited by 194
Metadata
- Authors
- Reynaud, Q., Lega, J.-C., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P., & Laporte, S.
- Affiliations
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Lyon 1 Université (FR)
- Inserm (FR)
- Corresponding author
- Lega, Jean-Christophe
- ORCID
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 13
- Issue
- 6
- Pages
- 595-608
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2020778344
- Cited by
- 179
- References
- 68
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 16 · 2023: 1 · 2022: 12 · 2021: 13 · 2020: 19 · 2019: 15 · 2018: 21 · 2017: 19 · 2016: 18 · 2015: 22 · 2014: 8
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Autoimmunity Reviews (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- antiphospholipid antibodies, venous thrombosis, arterial thrombosis, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, anti-prothrombin antibodies, antiphosphatidylserine antibodies, thrombosis risk, thromboprophylaxis
- MeSH terms
- Adult, Humans, Lupus Erythematosus, Systemic, Risk Factors, Thrombosis, Cohort Studies, Case-Control Studies, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, beta 2-Glycoprotein I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
